Association of provider HPV vaccination training with provider assessment of HPV vaccination status and recommendation of HPV vaccination

Abstract

The delivery of strong HPV vaccine recommendations hinges on the expertise of healthcare providers (HCPs) in assessing patients’ status and recommending HPV vaccination. We conducted a population-based cross-sectional study of HCPs practicing in Texas to examine the relationship between HPV vaccination training of HCPs and HPV vaccination status assessment and recommendation. Logistic regression analyses were used to assess the association between HCPs’ formal training and recency of training in HPV vaccination promotion or counseling with HPV vaccination status assessment and recommendation. Of the 1,283 HCPs who completed the online survey, 43% had received training in HPV vaccination promotion or counseling, 47% often/always assess HPV vaccination status, and 59% often/always recommend HPV vaccination. Compared with HCPs who received no training, those who received training had over four times higher odds (adjusted odds ratio [AOR]: 4.32; 95% CI: 3.06–6.10) of often/always assessing HPV vaccination status and over three and half times higher odds (AOR: 3.66; 95% CI: 2.73–4.90) of often/always recommending HPV vaccination. Furthermore, HCPs who recently received HPV vaccination training had higher odds of HPV vaccination status assessment and recommendations than those without training. Hispanic HCPs had higher odds of often/always assessing HPV vaccination status and recommending vaccination than did non-Hispanic White HCPs. Also, nurses and physician assistants had lower odds of often/always assessing HPV vaccination status and recommending HPV vaccination than did physicians. Targeted and continuous training of HCPs in HPV vaccination promotion or counseling is needed to increase HPV vaccination status assessment, recommendation, and uptake rates.

Healthcare Provider’s Perceived Self-Efficacy in HPV Vaccination Hesitancy Counseling and HPV Vaccination Acceptance

“…Indeed, since HPV vaccination acceptance is higher among adolescents than young adults, our finding points to the far-reaching effect of providers’ self-efficacy in increasing HPV vaccination acceptance across different patient demography [ 34 , 35 ]. We also assessed the influence of various provider-level characteristics, including provider age, race/ethnicity, experience, and practice type on HPV vaccination acceptance given that these variables are known predictors of HPV vaccination recommendation, a key determinant of vaccination acceptance [ 36 ]. Additionally, provider experience acquired either from years of counseling hesitant patients or from seeing a large number of patients is an essential factor associated with the self-efficacy of HCPs in counseling HPV-vaccine-hesitant patients [ 37 ].…”

“…HCPs would benefit from HPV vaccination training in line with the CDC ACIP guidelines for providers to counsel and recommend the HPV vaccines to their patients at every clinical encounter regardless of whether they were counseled but refused vaccination during their previous clinic visits [ 7 ]. Various training approaches have been found to be effective in increasing provider self-efficacy in counseling patients, improving motivation to recommend HPV vaccination, and increasing HPV vaccination initiation among adolescents [ 36 , 43 , 44 , 45 , 46 ]. For example, the use of a training module is effective in increasing knowledge and self-efficacy in HPV-related disease and vaccination counseling [ 44 ].…”

Human Papillomavirus Vaccinations: Provider Education to Enhance Vaccine Uptake

“…1 Seven percent of cancers in the United States are HPV-related cancers. 2 Every year, in the United States, HPV adds to more than 34 800 newly diagnosed oropharyngeal, anal, penile, cervical, vaginal, and vulvar cancers. 3,4 The HPV causes 90% of anal and cervical cancers, 70% of oropharyngeal cancers, 70% of vulvar and vaginal cancers, 60% of penile cancers, and can also cause genital warts.…”

“…Osaghae et al 2 stated that the economic burden of these cancers is substantial not only for the government at both the national and state levels but also for families and individuals. Roughly, 8 billion dollars a year in the United States are spent on direct medical expenses for the prevention and treatment of HPV-related cancers.…”

“…Roughly, 8 billion dollars a year in the United States are spent on direct medical expenses for the prevention and treatment of HPV-related cancers. 2 Dang et al 6 explained that the Centers for Disease Control and Prevention (CDC) approximated that 92% of HPV-related cancers might be preventable for those receiving the HPV 9-valent vaccine (Gardasil-9), which then mitigates the HPV-attributed cancer disparities before contraction. The 2-dose HPV vaccine for kids ages 11 to 12 years provides almost 100% protection against strains affiliated with cervical, vaginal, and vulvar cancers.…”